Understanding MiMedx Group’s Unusual Options Activity
On Wednesday, shares of MiMedx Group (NASDAQ:MDXG) saw unusual options activity. After the option alert, the stock price moved down to $12.4.
MiMedx Group Q2 EPS $(0.03) Beats $(0.05) Estimate, Sales $68.17M Beat $60.16M Estimate
MiMedx Group (NASDAQ:MDXG) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 62.5 percent increase over losses of $(0.08) per share from the same
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Northland Capital Markets Initiates Coverage On MiMedx Group with Outperform Rating, Announces Price Target of $23
Northland Capital Markets analyst Carl Byrnes initiates coverage on MiMedx Group (NASDAQ:MDXG) with a Outperform rating and announces Price Target of $23.
Earnings Scheduled For July 6, 2021
Companies Reporting Before The Bell
• SemiLEDs (NASDAQ:LEDS) is estimated to report earnings for its third quarter.
• MiMedx Group (NASDAQ:MDXG) is expected to report earnings for its first quarter.
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
Stocks That Hit 52-Week Highs On Tuesday
Tuesday's morning session saw 105 companies set new 52-week highs.
MiMedx Group Reports New Study Showed Potential For MIMEDX Purion Processed Dehydrated Human Amnion/Chorion Membrane To Modulate Pathological Scar Tissue Formation
Proposed Mechanism Suggests Potential Path to Improve Outcomes in Clinical Applications where the Regulation of Excessive Fibrosis Can Promote a Normal Healing Response